CG Oncology
CGON
121 hedge funds and large institutions have $1.96B invested in CG Oncology in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 19 reducing their positions, and 15 closing their positions.
221% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 19
83% more funds holding in top 10
Funds holding in top 10: 6 → 11 (+5)
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $1.37B → $1.96B (+$597M)
13% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $1.95M
12.85% more ownership
Funds ownership: 64.94% → 77.79% (+13%)
9% more funds holding
Funds holding: 111 → 121 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.5M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$60.2M |
| 3 |
BlackRock
New York
|
+$55.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$25.2M |
| 5 |
O
OrbiMed
New York
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$49.9M |
| 2 |
YF
Yu Fan
|
-$49.6M |
| 3 |
AWGLSCP
ABG-WTT Global Life Science Capital Partners
Central, Hong Kong,
Hong Kong
|
-$14.7M |
| 4 |
Walleye Capital
New York
|
-$6.66M |
| 5 |
CF
Corebridge Financial
Houston,
Texas
|
-$6.02M |
CGON Hedge Fund Activity: Q3 2024 in Review
121 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q3 2024, worth a combined $1.96B — up 44% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CGON positions and 15 closed out — a net gain of 10 holders — while 61 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $99.5M. The largest seller was BVF Inc, cutting an estimated $49.9M.
- 121 institutional investors held CG Oncology (CGON) as of Q3 2024, up from 111 in Q2 2024.
- Funds reported $1.96B of CG Oncology stock for Q3 2024, up 44% quarter-over-quarter.
- 25 funds opened new CG Oncology positions in Q3 2024 and 15 closed out, a net change of +10 holders.
- The largest CG Oncology buyer in Q3 2024 was Vanguard Group, an estimated $99.5M added.
- The largest CG Oncology seller in Q3 2024 was BVF Inc, an estimated $49.9M sold.
Based on aggregated 13F filings for Q3 2024.